You can buy or sell Novartis and other stocks, options, ETFs, and crypto commission-free!
Novartis AG, also called Novartis, is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. Read More The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Basel, Basel-Stadt (Basle Town)
52 Week High
52 Week Low
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
Novartis NVS announced that its eye-care unit, Alcon acquired privately-held, U.S.-based medical device development company, PowerVision, Inc.
Sandoz acquires PowerVision for $285M
Novartis (NYSE:NVS) unit Sandoz has acquired fluid-based intraocular lens maker PowerVision for $285M. It can earn additional payments based on the achievement of certain regulatory and commercial milestones starting in 2023. Alcon says it reaffirms its 2023 financial outlook provided in Q4 2018. NVS is down a fraction premarket....
Expected Apr 24, Pre-Market